06-08-2026 21:08 via drugs.com

FDA Approves First Drug, Orzeyful, for Full Range of Narcolepsy Symptoms

THURSDAY, Aug. 6, 2026 -- The U.S. Food and Drug Administration has approved Orzeyful (oveporexton) tablets for the treatment of narcolepsy type 1 in adults.
Orzeyful marks the first medicine approval for the full range of symptoms associated with...
Read more »

Pharmaceutical Industry news



Burnout Common Among Psychiatric Mental Health Registered Nurses
FDA Approves First Self-Balancing, Personal Exoskeleton
Suboptimal Adherence to Brain Health Recommendations Common in Early Alzheimer Disease
Genomic Newborn Screening Could ID Cancer Predisposition Syndrome
Report Highlights Substance Use in Young Adults in U.S. in 2025
Imaging Turnaround Time Increased From 2023 to 2024
Many With Atypical Alzheimer Disease Do Not Qualify for Anti-Amyloid Therapy
Stair Climbing Associated With Reduction in Cardiovascular, All-Cause Mortality
Socioeconomic Inequalities Tied to Functional Aging
Flu Treatment With Oseltamivir Linked to Reduced Risk for Pediatric ICU Admissions, Length of Stay
First Metatarsophalangeal Joint Arthrodesis Eases Painful Hallux Rigidus
Menopausal Hormone Therapy Use Linked to Lower Risk for Alzheimer Disease
Study IDs Neurobiological Roots of Sensory Over-Responsivity
2005 to 2023 Saw Decrease in DXA Testing for Osteoporosis Screening
Desktop versie